You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Valneva completes recruitment for Phase I/II COVID-19 vaccine study

French speciality vaccine company Valneva has completed recruitment for a Phase I/II study of its inactivated, adjuvanted COVID-19 vaccine, with the first results expected in April 2021.